ProstaGene
ProstaGene develops gene-based cancer diagnostics and therapeutic screening. It combines proprietary molecular diagnostics with novel therapeutic screening and patent-backed technologies to pursue cancer treatments. The company focuses on gene-based prostate cancer testing and metastasis prevention, including a platform for preclinical therapy testing in immune-competent mice and therapies with promising preclinical data. It operates as a biotech startup that seeks financing to partner, out-license, or contracted-develop its technologies, including its gene signature tests and metastasis strategies. The business model centers on partnering with biopharma and healthcare organizations to commercialize diagnostics and therapeutics for cancer.
ProstaGene
ProstaGene develops gene-based cancer diagnostics and therapeutic screening. It combines proprietary molecular diagnostics with novel therapeutic screening and patent-backed technologies to pursue cancer treatments. The company focuses on gene-based prostate cancer testing and metastasis prevention, including a platform for preclinical therapy testing in immune-competent mice and therapies with promising preclinical data. It operates as a biotech startup that seeks financing to partner, out-license, or contracted-develop its technologies, including its gene signature tests and metastasis strategies. The business model centers on partnering with biopharma and healthcare organizations to commercialize diagnostics and therapeutics for cancer.